Literature DB >> 9094980

Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

T Luther1, V Magdolen, S Albrecht, M Kasper, C Riemer, H Kessler, H Graeff, M Müller, M Schmitt.   

Abstract

uPAR (CD87), the receptor for the urokinase-type plasminogen activator (uPA) facilitates tumor cell invasion and metastasis by focusing uPA proteolytic activity to the cell surface. As uPAR exists in various molecular forms, it is desirable to use well defined antibodies for analyses of uPAR antigen expression in human malignant tumors by immunological methods. Therefore, twelve monoclonal antibodies (MAbs) directed against uPAR were generated by using nonglycosylated, recombinant human uPAR (spanning amino acids 1 to 284), expressed in Escherichia coli, as the immunogen. The reaction pattern of these MAbs with the immunogen and a series of carboxyl-terminally truncated versions of uPAR demonstrated that at least six different epitopes of uPAR are recognized. All MAbs reacted under reducing conditions in immunoblot analyses with E. coli-expressed uPA and also with highly glycosylated, functionally intact, recombinant human uPAR expressed in Chinese hamster ovary (CHO) cells. Seven of the MAbs recognized CHO uPAR under nonreducing conditions as well. By flow cytofluorometric analyses, three of these MAbs were shown to bind to native human uPAR present on the cell surface of monocytoid U937 cells with MAb IIIF10 being the best. Saturation of uPAR with uPA on U937 cells completely blocked interaction of MAb IIIF10 with uPAR (mapped epitope, amino acids 52 to 60 of domain I of uPAR). In turn, preincubation of U937 cells with MAb IIIF10 efficiently reduced binding of uPA to uPAR, indicating that the epitope detected by MAb IIIF10 is located within or closely to the uPA-binding site of uPAR, and thus, this site may be a target to influence uPA/uPAR-mediated proteolysis in tumors. Binding of MAbs IID7 or IIIB11 (mapped epitope, amino acids 125 to 132 of domain II of uPAR) to uPAR is not affected when uPAR is occupied by uPA. As these MAbs reacted strongly with cellular uPAR antigen in formalin-fixed paraffin-embedded tumor sections, the domain-II-specific antibodies IID7 and IIIB11 may be useful for immunohistochemical studies of uPAR expression in tissue remodeling processes in tumor invasion. In conclusion, we have devised well defined and epitope-mapped MAbs to uPAR that are highly specific tools for detection and targeting of uPAR in tumor tissue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094980      PMCID: PMC1858180     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Tissue factor expression in normal and abnormal mammary gland.

Authors:  T Luther; C Flössel; S Albrecht; M Kotzsch; M Müller
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

2.  Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue.

Authors:  C Flössel; T Luther; M Müller; S Albrecht; M Kasper
Journal:  Histochemistry       Date:  1994-07

3.  Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.

Authors:  M Ploug; H Rahbek-Nielsen; V Ellis; P Roepstorff; K Danø
Journal:  Biochemistry       Date:  1995-10-03       Impact factor: 3.162

4.  Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.

Authors:  V Magdolen; P Rettenberger; M Koppitz; L Goretzki; H Kessler; U H Weidle; B König; H Graeff; M Schmitt; O Wilhelm
Journal:  Eur J Biochem       Date:  1996-05-01

5.  Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.

Authors:  C Duggan; T Maguire; E McDermott; N O'Higgins; J J Fennelly; M J Duffy
Journal:  Int J Cancer       Date:  1995-05-29       Impact factor: 7.396

Review 6.  Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.

Authors:  M Schmitt; O Wilhelm; F Jänicke; V Magdolen; U Reuning; H Ohi; N Moniwa; H Kobayashi; U Weidle; H Graeff
Journal:  J Obstet Gynaecol (Tokyo 1995)       Date:  1995-04

7.  A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.

Authors:  P Rettenberger; O Wilhelm; H Oi; U H Weidle; L Goretzki; M Koppitz; F Lottspeich; B König; U Pessara; M D Kramer
Journal:  Biol Chem Hoppe Seyler       Date:  1995-10

8.  Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.

Authors:  H K Lau; M Kim; J Koo; B Chiu; D Murray
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

9.  Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.

Authors:  V Magdolen; P Rettenberger; A Lopens; H Oi; F Lottspeich; J Kellermann; S Creutzburg; L Goretzki; U H Weidle; O Wilhelm
Journal:  Electrophoresis       Date:  1995-05       Impact factor: 3.535

10.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells.

Authors:  S M Kanse; C Kost; O G Wilhelm; P A Andreasen; K T Preissner
Journal:  Exp Cell Res       Date:  1996-05-01       Impact factor: 3.905

View more
  13 in total

1.  Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

Authors:  G van der Pluijm; B Sijmons; H Vloedgraven; C van der Bent; J W Drijfhout; J Verheijen; P Quax; M Karperien; S Papapoulos; C Löwik
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Urokinase receptor orchestrates the plasminogen system in airway epithelial cell function.

Authors:  Ceri E Stewart; Ian Sayers
Journal:  Lung       Date:  2013-02-14       Impact factor: 2.584

3.  A novel peptide blocking cancer cell invasion by structure-based drug design.

Authors:  Yuki Yamada; Seiji Kanayama; Fuminori Ito; Noriyuki Kurita; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-07-31

4.  A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Authors:  Haydyn D T Mertens; Magnus Kjaergaard; Simon Mysling; Henrik Gårdsvoll; Thomas J D Jørgensen; Dmitri I Svergun; Michael Ploug
Journal:  J Biol Chem       Date:  2012-08-15       Impact factor: 5.157

5.  Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.

Authors:  S R Harvey; S N Sait; Y Xu; J L Bailey; R M Penetrante; G Markus
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

6.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

7.  Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.

Authors:  Natalie Falkenberg; Nataša Anastasov; Annalisa Schaub; Vanja Radulovic; Manfred Schmitt; Viktor Magdolen; Michaela Aubele
Journal:  Oncotarget       Date:  2015-04-10

8.  Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.

Authors:  Bettina Grismayer; Susanne Sölch; Bastian Seubert; Thomas Kirchner; Sonja Schäfer; Gustavo Baretton; Manfred Schmitt; Thomas Luther; Achim Krüger; Matthias Kotzsch; Viktor Magdolen
Journal:  Mol Cancer       Date:  2012-08-24       Impact factor: 27.401

Review 9.  Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.

Authors:  Dan Li; Shuanglong Liu; Hong Shan; Peter Conti; Zibo Li
Journal:  Theranostics       Date:  2013-06-29       Impact factor: 11.556

10.  Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.

Authors:  R Hildenbrand; N Arens
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.